High doses of favipiravir combat SARS-CoV-2 in hamsters 12 October 2020 | By Victoria Rees (Drug Target Review) A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
Researchers suggest blocking factor D protein could combat SARS-CoV-2 9 October 2020 | By Victoria Rees (Drug Target Review) A team has said that inhibiting the factor D protein could prevent SARS-CoV-2 from turning the immune system against healthy cells.
CRISPR used to eliminate cancers caused by fusion genes 9 October 2020 | By Hannah Balfour (Drug Target Review) Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
New class of inhibitors protect mice from neurodegeneration 9 October 2020 | By Victoria Rees (Drug Target Review) So called "interface inhibitors" could be used to protect against neurodegeneration, researchers have said.
SARS-CoV-2-targeting antibodies persist for at least three months in COVID-19 patients 9 October 2020 | By Hannah Balfour (Drug Target Review) Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
Single-nucleus transcriptomics reveals novel epilepsy targets 8 October 2020 | By Hannah Balfour (Drug Target Review) Study reveals which neurons are most affected by epilepsy, presenting novel targets for seizure drug discovery and development.
SARS-CoV-2 mechanism of infection revealed using cryo-electron microscopy 8 October 2020 | By Victoria Rees (Drug Target Review) Researchers have found that the surface of SARS-CoV-2 can take on at least 10 different structural states when in contact with ACE2.
Researchers identify a potential remdesivir resistance mechanism in SARS-CoV-2 8 October 2020 | By Hannah Balfour (Drug Target Review) Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
Researchers make steps towards a universal flu vaccine 8 October 2020 | By Victoria Rees (Drug Target Review) A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
Build-up in the lungs could be targeted by future severe COVID-19 treatments 7 October 2020 | By Hannah Balfour (Drug Target Review) Breaking down or slowing the production of a hyaluronan jelly which builds up in the lungs of some severe COVID-19 patients could reduce respiratory distress and prevent death.
NIH to support 85 highly innovative research projects 7 October 2020 | By Hannah Balfour (Drug Target Review) The US National Institutes of Health (NIH) will award a total of $251 million over five years to 85 high-risk, high-reward biomedical or behavioural research projects.
Scientists propose treating SARS-CoV-2 with sofosbuvir and remdesivir 7 October 2020 | By Victoria Rees (Drug Target Review) Researchers have posited that SARS-CoV-2 could be combatted by sofosbuvir, in combination with other antivirals such as remdesivir.
Lead drug candidate identified as potential neuroblastoma treatment 7 October 2020 | By Victoria Rees (Drug Target Review) Using hit-to-lead processes, researchers have discovered that KSP inhibitors prevent tumour growth and prolong survival in mice with neuroblastoma.
Small molecules to reduce cellular stress identified by HTS 6 October 2020 | By Hannah Balfour (Drug Target Review) Scientists used high throughput screening (HTS) to identify molecules that protect against cellular stress in murine skin cells.
2020 Nobel Prize goes to discoverers of hepatitis C 6 October 2020 | By Hannah Balfour (Drug Target Review) The 2020 Nobel Prize in Physiology or Medicine has been bestowed upon researchers who helped identify the hepatitis C virus in the 1970s.
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-750x500.jpg)
![Syringe drawing liquid from a vial labelled 'REMDESIVIR', on a background of abstract SARS-CoV-2 particles [Credit: ffikretow@hotmail.com / Shutterstock.com].](https://www.drugtargetreview.com/wp-content/uploads/remdesivir-SARS-CoV-2-scaled-e1602154798857.jpg)
